Figure 5: Td maintenance of GCs and serum IgG2b/c ANAs.

(a–e,g–i) SLC^−/− mice were treated with anti-CD40L or isotype control antibodies, and killed after 6 days (b) or 5 weeks (c–e,g–i). (a) Experimental setup. (b) Graph shows % GCs per follicles (FO, two independent observers). (c–h) Flow cytometry analysis of spleen cells. (c) Graph shows % CD95⁺GL7⁺ cells among CD19⁺ cells. (d) Graph shows % CD4⁺PD-1^hi cells among CD4⁺ cells. (e) Graph shows % large cells of total FO B cells. (f) Expression of cell surface IgG2b/c after gating on GL7⁺ and CD19⁺ cells in SLC^−/− mice. Note that these are untreated. (g) % IgG2b/c⁺ cells among CD19⁺ cells. (h) Expression of IgG2b/c on GL7⁺ and GL7⁻ cell populations among CD19⁺ cells. (i) Graphs show fold change of serum IgG2b and IgG2c ANAs before and after treatment. Data are representative and pooled (b–e,g) from at least two independent experiments. Each symbol represents one mouse. Error bars represent s.e.m. P values were determined using a two-tailed t-test. *P<0.05, ***P<0.001; i.v., intravenous; NS, not significant.